Active • Host: HEK293 cells • AA: 24-213 • Tag: N-terminal His • MW: 22.5 kDa
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Sclerostin (human, recombinant)

Item No. 44192

Product Insert (PDF)
Technical Information
Synonyms
  • SOST
Purity
≥90% estimated by SDS-PAGE
Endotoxin Testing
<1.0 EU per g of the protein as determined by the LAL method
Source
Active recombinant human N-terminal His-tagged sclerostin expressed in HEK293 cells
Amino Acids
24-213
MW
22.5 kDa
Formulation (Request formulation change)
Lyophilized from sterile PBS, pH 7.4
UniProt Accession №
Q9BQB4
Shipping & Storage Information
Storage
-80°C
Shipping
Dry ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    50 µg

    $195

    Add
    Product Description

    Sclerostin is a secreted glycoprotein and a member of the DAN/Cerberus protein family involved in Wnt signaling in bone.1,2,3 It contains a cystine-knot motif and heparin binding site and is expressed by osteocytes and cementocytes.3,4 Sclerostin competes with Wnt ligands for binding to LDL receptor-related protein 5/6 (LRP5/6), where it acts as a Wnt inhibitor and inhibits osteoblast activity.1,2 It also acts as an antagonist against several members of the bone morphogenetic protein (BMP) family. Inhibition of sclerostin via monoclonal antibodies increases bone mineral density in mice.3 Loss-of-function mutations in the gene encoding sclerostin, SOST, are associated with sclerosteosis, craniodiaphyseal dysplasia (CDD), and van Buchem disease.1 Formulations containing a monoclonal antibody against sclerostin have been used in the treatment of osteoporosis. Cayman’s Sclerostin (human, recombinant) protein can be used for binding assays. This protein consists of 197 amino acids and has a calculated molecular weight of 22.5 kDa. By SDS-PAGE, under reducing conditions, the apparent molecular mass of the protein is approximately 30 kDa due to glycosylation.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Pietrzyk, B., Smertka, M., and Chudek, J. Sclerostin: Intracellular mechanisms of action and its role in the pathogenesis of skeletal and vascular disorders. Adv. Clin. Exp. Med. 26(8), 1283-1291 (2017).

    2. Ke, H.Z., Richards, W.G., Li, X., et al. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr. Rev. 33(5), 747-783 (2012).

    3. Veverka, V., Henry, A.J., Slocombe, P.M., et al. Characterization of the structural features and interactions of sclerostin: Molecular insight into a key regulator of Wnt-mediated bone formation. The Journal of Biological Chemisty 284(16), 10890-10900 (2009).

    4. Jäger, A., Götz, W., Lossdörfer, S., et al. Localization of SOST/sclerostin in cementocytes in vivo and in mineralizing periodontal ligament cells in vitro. J. Periodontal. Res. 45(2), 246-254 (2010).